Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
October 27, 2025 07:00 ET | Source: EDAP TMS S.A.

EDAP to Participate in the UBS Global Healthcare Conference

EDAP to Participate in the UBS Global Healthcare Conference Company to Host 1x1 Investor Meetings on Monday, November 10th, 2025 AUSTIN, Texas, October 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the...
October 23, 2025 07:00 ET | Source: EDAP TMS S.A.

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025

EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 Company to host conference call and webcast on Thursday, November 6th at 8:30am EST AUSTIN, Texas, October 23, 2025 -- EDAP...
October 20, 2025 08:30 ET | Source: EDAP TMS S.A.

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU Lyon, France – October 20, 2025 – EDAP TMS SA (Nasdaq: EDAP) (“EDAP”...
October 18, 2025 03:00 ET | Source: AdvanCell

AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer

Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer...
October 17, 2025 14:06 ET | Source: BCC Research LLC

Targeted Alpha Therapies Market to Grow at 44% CAGR Globally by 2030

Boston, Oct. 17, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Targeted Alpha Therapies for Cancer Treatment: Global Market” was valued at $199.6 million in 2024, and is...
October 16, 2025 08:00 ET | Source: Profound Medical Corp.

Profound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure Milestone

TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
October 16, 2025 02:00 ET | Source: AdvanCell

AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors

Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a...
October 15, 2025 02:30 ET | Source: Curium

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan...
October 14, 2025 08:30 ET | Source: Profound Medical Corp.

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

TORONTO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...